Vaxcyte (PCVX) Total Non-Current Liabilities (2019 - 2025)
Vaxcyte (PCVX) posted quarterly Total Non-Current Liabilities of $317.1 million for Q4 2025, up 54.39% year-over-year from $205.4 million in Q4 2024, and up 54.39% quarter-over-quarter from $205.4 million in Q4 2024.
Vaxcyte (PCVX) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Vaxcyte (PCVX) has reported Total Non-Current Liabilities for 7 consecutive years, with $317.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 54.39% year-over-year to $317.1 million; the TTM figure through Dec 2025 stood at $317.1 million (up 54.39% YoY), while the FY2025 annual figure was $317.1 million, up 54.39% from the prior year.
- Total Non-Current Liabilities grew to $317.1 million in Q4 2025 per PCVX's latest filing, from $205.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $317.1 million in Q4 2025 and bottomed at $40.2 million in Q4 2021.
- Historically, Total Non-Current Liabilities has averaged $92.4 million across 5 years, with a median of $54.0 million in 2021.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities declined 22.11% — and 2023, when it surged 218.61%.
- Vaxcyte's Total Non-Current Liabilities stood at $40.2 million in 2021, then jumped by 30.66% to $52.6 million in 2022, then soared by 218.61% to $167.4 million in 2023, then gained by 22.66% to $205.4 million in 2024, then soared by 54.39% to $317.1 million in 2025.
- Business Quant data shows PCVX's Total Non-Current Liabilities at $317.1 million in Q4 2025, $205.4 million in Q4 2024, and $167.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 317.11 Mn |
| Dec 31, 2024 | 205.40 Mn |
| Dec 31, 2023 | 167.45 Mn |
| Sep 30, 2023 | 93.34 Mn |
| Jun 30, 2023 | 69.44 Mn |
| Mar 31, 2023 | 63.39 Mn |
| Dec 31, 2022 | 52.56 Mn |
| Sep 30, 2022 | 52.67 Mn |
| Jun 30, 2022 | 45.03 Mn |
| Mar 31, 2022 | 43.08 Mn |
| Dec 31, 2021 | 40.22 Mn |
| Sep 30, 2021 | 48.01 Mn |
| Jun 30, 2021 | 40.93 Mn |
| Mar 31, 2021 | 55.31 Mn |
| Dec 31, 2020 | 46.87 Mn |
| Sep 30, 2020 | 39.61 Mn |
| Jun 30, 2020 | 32.90 Mn |
| Dec 31, 2019 | 11.52 Mn |